These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9835010)

  • 1. [Cardiovascular and metabolic diseases. Imidazolin-antagonists and the sympathetic nervous system].
    Z Kardiol; 1998 Oct; 87(10 Suppl):1-4. PubMed ID: 9835010
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of antihypertensive therapies on the sympathetic nervous system.
    de Champlain J; Karas M; Toal C; Nadeau R; Larochelle P
    Can J Cardiol; 1999 Mar; 15 Suppl A():8A-14A. PubMed ID: 10205251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cardiovascular disease: an evidence-based clinical aid.
    Cradick NH
    Med J Aust; 2004 Feb; 180(4):197-8; author reply 198. PubMed ID: 14960146
    [No Abstract]   [Full Text] [Related]  

  • 4. A polypill for secondary prevention: time to move from intellectual debate to action.
    Fuster V; Sanz G
    Nat Clin Pract Cardiovasc Med; 2007 Apr; 4(4):173. PubMed ID: 17380163
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cardiology 2008].
    Hoppe UC; Erdmann E
    Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1341-3. PubMed ID: 18553258
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
    Chikhladze NM
    Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of sympathetic activation in cardiovascular disease.
    Cohen JD; Egan BM
    Postgrad Med; 2003 Dec; 114(6 Suppl Role):4-10. PubMed ID: 19667664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Living up to 100 years of Bayer Healthcare cardiovascular protection - Bayer Healthcare Cardiovascular : 20 years of participation in the South African cardiovascular community.
    Cardiovasc J Afr; 2009; 20(1):91-4. PubMed ID: 19287826
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical practice guideline for cardiovascular risk management in the Netherlands.
    Smulders YM; Burgers JS; Scheltens T; van Hout BA; Wiersma T; Simoons ML;
    Neth J Med; 2008 Apr; 66(4):169-74. PubMed ID: 18424866
    [No Abstract]   [Full Text] [Related]  

  • 10. [Endothelial dysfunction and metabolic effects of nitric oxide in human].
    Kolesnichenko OIu; Filatova LM; Krivitsina ZA; Voronkov IuI
    Fiziol Cheloveka; 2003; 29(5):74-81. PubMed ID: 14611088
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans.
    Galloway SD; De Vito G; McClure S; Nimmo MA; McMurray JJ
    Clin Sci (Lond); 2000 Sep; 99(3):223-30. PubMed ID: 11787475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing chronobiology of cardiovascular outcome following prophylaxis.
    Jose VM; Sharma N; Hota D; Pandhi P
    Nepal Med Coll J; 2007 Mar; 9(1):1-5. PubMed ID: 17593669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease.
    Nap A; Balt JC; Mathy MJ; Van Zwieten PA
    Auton Autacoid Pharmacol; 2003; 23(5-6):285-96. PubMed ID: 15255813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased activity of the sympathetic nervous system and the possibilities for therapeutic influence].
    Soucek M; Nevrlka J; Rihácek I; Frána P; Plachý M
    Vnitr Lek; 2007 May; 53(5):554-9. PubMed ID: 17642445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of prostacyclin and its analogues in the treatment of cardiovascular disease.
    Fink AN; Frishman WH; Azizad M; Agarwal Y
    Heart Dis; 1999; 1(1):29-40. PubMed ID: 11720602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of cardiovascular events in diabetes.
    Malcolm J; Meggison H; Sigal R
    Clin Evid; 2003 Dec; (10):690-714. PubMed ID: 15555116
    [No Abstract]   [Full Text] [Related]  

  • 19. Sympathetic activity and clinical outcome in dialysis patients.
    Siddiqi L; Blankestijn PJ
    Hypertension; 2009 Jul; 54(1):e8; author reply e9. PubMed ID: 19506094
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of cardiovascular events in diabetes.
    Sigal R; Malcolm J; Arnaout A
    Clin Evid; 2006 Jun; (15):623-45. PubMed ID: 16973029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.